Who is sponsoring NCT03871205?

NCT03871205 is sponsored by Shenzhen People's Hospital.

What drugs are being tested in NCT03871205?

Interventions in NCT03871205: Neoantigen loaded DC vaccine.

What condition does NCT03871205 study?

NCT03871205 studies Carcinoma, Non-Small Cell Lung, Carcinoma, Small Cell Lung.

Is NCT03871205 still recruiting?

NCT03871205 is currently status unknown. Last updated 12 March 2019.

Last reviewed 2019-03-12 · How we verify

NCT03871205

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer

Status unknown Phase 1 Last updated 12 March 2019

What this trial tests

Phase 1 trial testing Neoantigen loaded DC vaccine in Carcinoma, Non-Small Cell Lung in 30 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
30 June 2020

30 December 2020

Quick facts

Lead sponsor	Shenzhen People's Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 April 2019
Primary completion	30 June 2020
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

Neoantigen loaded DC vaccine

Conditions studied

Carcinoma, Non-Small Cell Lung — all drugs for Carcinoma, Non-Small Cell Lung →
Carcinoma, Small Cell Lung — all drugs for Carcinoma, Small Cell Lung →

Sponsor

Shenzhen People's Hospital

Who can join

Adults 18 to 70, any sex, with Carcinoma, Non-Small Cell Lung or Carcinoma, Small Cell Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Various of immunotherapies are now widely applied in the treatment of lung cancer. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are highly suitable for the development of cancer vaccines. The study aims to evaluate the safety and efficacy of neoantigen-loaded dendritic cell (DC) vaccines for refractory lung cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Tumor neoantigens: from basic research to clinical applications.
Jiang T, Shi T, Zhang H, Hu J, et al · · 2019 · cited 276× · PMID 31492199 · DOI 10.1186/s13045-019-0787-5
Research progress on dendritic cell vaccines in cancer immunotherapy.
Yu J, Sun H, Cao W, Song Y, et al · · 2022 · cited 130× · PMID 35074008 · DOI 10.1186/s40164-022-00257-2
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
Selecting Target Antigens for Cancer Vaccine Development.
Buonaguro L, Tagliamonte M. · · 2020 · cited 97× · PMID 33080888 · DOI 10.3390/vaccines8040615
Dendritic Cell-Based Immunotherapy in Lung Cancer.
Stevens D, Ingels J, Van Lint S, Vandekerckhove B, et al · · 2020 · cited 55× · PMID 33679709 · DOI 10.3389/fimmu.2020.620374
Novel Biomarkers for Personalized Cancer Immunotherapy.
Shindo Y, Hazama S, Tsunedomi R, Suzuki N, et al · · 2019 · cited 35× · PMID 31443339 · DOI 10.3390/cancers11091223
Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications.
Tang L, Zhang R, Zhang X, Yang L. · · 2021 · cited 34× · PMID 34381724 · DOI 10.3389/fonc.2021.701777

Verify or expand the search:

Other recruiting trials for Carcinoma, Non-Small Cell Lung

Currently open trials in the same condition.

NCT07227298 — Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer · Phase 1, PHASE2 · recruiting
NCT06868277 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic · Phase 3 · recruiting
NCT05358249 — Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · Phase 1, PHASE2 · active not recruiting
NCT04389632 — A Study of Sigvotatug Vedotin in Advanced Solid Tumors · Phase 1 · recruiting

Other Shenzhen People's Hospital trials

Trials by the same sponsor.

NCT07512050 — Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity · NA · not yet recruiting
NCT07366255 — Safety and Efficacy of Tripalmitoleoylglycerol in the Treatment of Dermatitis · NA · completed
NCT07366229 — Topical Application of Engineered Lactobacillus Reuteri With a Zinc Sulfate-Tannic Acid MPN Coating for Acne · Phase 2 · recruiting
NCT07266532 — Topical Lactobacillus Crispatus for Skin Barrier Dysfunction in Obesity · NA · completed
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03871205 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen People's Hospital
Last refreshed: 12 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03871205.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing